Find therapies in clinical trials near you – page 278

Study on the Effectiveness and Safety of Obinutuzumab for Patients with Class III or IV Lupus Nephritis

Study on Mirikizumab for Children and Teens with Moderate to Severe Ulcerative Colitis

Study on Mirikizumab for Children and Teens with Moderate to Severe Ulcerative Colitis

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Study of BMS-986288 and Nivolumab for Patients with Advanced Solid Tumors

Study of BMS-986288 and Nivolumab for Patients with Advanced Solid Tumors

Study of Brentuximab Vedotin, Adriamycin, Vinblastine, and Dacarbazine for Children with Advanced Stage Hodgkin Lymphoma

Study on Guselkumab and Etanercept for Treating Chronic Plaque Psoriasis in Children Aged 6 to 17 Years

Study on Guselkumab and Etanercept for Treating Chronic Plaque Psoriasis in Children Aged 6 to 17 Years

Study on SENS-501 for Children with Severe Hearing Loss Due to Otoferlin Gene Mutations

Study on SENS-501 for Children with Severe Hearing Loss Due to Otoferlin Gene Mutations

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Study of BMS-986158 Alone and with Ruxolitinib or Fedratinib for Patients with Intermediate or High Risk Myelofibrosis

Study of BMS-986158 Alone and with Ruxolitinib or Fedratinib for Patients with Intermediate or High Risk Myelofibrosis